Drug Patents Expiring in 2039
1. Adrenalin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11083698 | PAR STERILE PRODUCTS | Epinephrine compositions and containers |
Mar, 2039
(14 years from now) | |
| US10653646 | PAR STERILE PRODUCTS | Epinephrine compositions and containers |
Mar, 2039
(14 years from now) | |
| US11207280 | PAR STERILE PRODUCTS | Epinephrine compositions and containers |
Mar, 2039
(14 years from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 21 April, 2023
Treatment: To increase mean arterial blood pressure in adult patients with hypotension associated with septic shock
Dosage: SOLUTION;INTRAVENOUS
ADRENALIN family patents
2. Airduo Digihaler patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US11000653 (Pediatric) | TEVA PHARM | Inhaler |
Jun, 2039
(15 years from now) | |
| US11344685 | TEVA PHARM | Drug delivery device with electronics |
Sep, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
| New Product(NP) | Jan 27, 2020 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 12 July, 2019
Treatment: NA
Dosage: POWDER;INHALATION
AIRDUO DIGIHALER family patents
3. Anjeso patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11458145 | BAUDAX | Methods of administering intravenous meloxicam in a bolus dose |
Mar, 2039
(14 years from now) | |
| US10881663 | BAUDAX | Method of treating pain in elderly patients with mild renal impairment |
Mar, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 20, 2023 |
Drugs and Companies using MELOXICAM ingredient
Market Authorisation Date: 20 February, 2020
Treatment: Management of moderate-to-severe pain by injection; Management of moderate-to-severe pain by intravenous injection in patients with mild renal impairment
Dosage: SOLUTION;INTRAVENOUS
ANJESO family patents
4. Annovera patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10780047 | MAYNE PHARMA | Method of providing birth control |
Feb, 2039
(14 years from now) | |
| US10632066 | MAYNE PHARMA | Method of providing birth control |
Feb, 2039
(14 years from now) | |
| US10765628 | MAYNE PHARMA | Method of providing birth control |
Feb, 2039
(14 years from now) | |
| US10925882 | MAYNE PHARMA | System for providing birth control |
Jun, 2039
(15 years from now) | |
| US10918649 | MAYNE PHARMA | System for providing birth control |
Jun, 2039
(15 years from now) | |
| US11529308 | MAYNE PHARMA | System for providing birth control |
Jun, 2039
(15 years from now) | |
| US10940157 | MAYNE PHARMA | System for providing birth control |
Jun, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
Drugs and Companies using ETHINYL ESTRADIOL; SEGESTERONE ACETATE ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: Method of preventing pregnancy by inserting a vaginal system containing 103 mg of segesterone acetate and 17.4 mg ethinyl estradiol into a vagina for up to thirteen 21/7-day (in/out) cycles; Method of...
Dosage: RING;VAGINAL
ANNOVERA family patents
5. Aristada patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11273158 | ALKERMES INC | Aripiprazole dosing strategy |
Apr, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 05, 2020 |
Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient
NCE-1 date: 06 October, 2019
Market Authorisation Date: 05 October, 2015
Treatment: Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ARISTADA family patents
6. Aristada Initio Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11273158 | ALKERMES INC | Aripiprazole dosing strategy |
Apr, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 05, 2020 |
Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient
NCE-1 date: 06 October, 2019
Market Authorisation Date: 29 June, 2018
Treatment: Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ARISTADA INITIO KIT family patents
7. Armonair Digihaler patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US11357935 (Pediatric) | TEVA PHARM | Drug delivery device with electronics |
Mar, 2039
(14 years from now) | |
|
US11000653 (Pediatric) | TEVA PHARM | Inhaler |
Jun, 2039
(15 years from now) | |
| US11344685 | TEVA PHARM | Drug delivery device with electronics |
Sep, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 09, 2024 |
| New Strength(NS) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
| New Product(NP) | Jan 27, 2020 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 08 April, 2022
Treatment: NA
Dosage: POWDER;INHALATION
ARMONAIR DIGIHALER family patents
8. Baqsimi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10765602 | AMPHASTAR PHARMS INC | Medication delivery systems and methods |
Sep, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 24, 2022 |
Drugs and Companies using GLUCAGON ingredient
Market Authorisation Date: 24 July, 2019
Treatment: NA
Dosage: POWDER;NASAL
BAQSIMI family patents
9. Brexafemme patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11534433 | SCYNEXIS | Antifungal agents with enhanced activity in acidic pH |
Jun, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 01, 2026 |
| New Indication(I-903) | Nov 30, 2025 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 01, 2031 |
Drugs and Companies using IBREXAFUNGERP CITRATE ingredient
NCE-1 date: 01 June, 2030
Market Authorisation Date: 01 June, 2021
Treatment: Reduction in the incidence of recurrent vulvovaginal candidiasis (rvvc) in adult and post-menarchal pediatric females
Dosage: TABLET;ORAL
BREXAFEMME family patents
10. Bylvay patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10975046 | ALBIREO | Crystal modifications of odevixibat |
Jun, 2039
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11365182 | ALBIREO | Crystal modifications of odevixibat |
Jun, 2039
(15 years from now) | |
| US11801226 | ALBIREO | Pharmaceutical formulation of odevixibat |
Jun, 2039
(15 years from now) | |
| US11802115 | ALBIREO | Pharmaceutical formulation of odevixibat |
Jun, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2026 |
| Orphan Drug Exclusivity(ODE-436) | Jun 13, 2030 |
| New Indication(I-918) | Jun 13, 2026 |
| Orphan Drug Exclusivity(ODE-363) | Jul 20, 2028 |
Drugs and Companies using ODEVIXIBAT ingredient
NCE-1 date: 20 July, 2025
Market Authorisation Date: 20 July, 2021
Treatment: Method of reducing serum bile acids in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic)
Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL
BYLVAY family patents
11. Camcevi Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11717555 | ACCORD | Pharmaceutical compositions having a selected release duration |
Jan, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 25, 2024 |
Drugs and Companies using LEUPROLIDE MESYLATE ingredient
Market Authorisation Date: 25 May, 2021
Treatment: NA
Dosage: EMULSION;SUBCUTANEOUS
CAMCEVI KIT family patents
12. Caplyta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11690842 | INTRA-CELLULAR | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
Aug, 2039
(15 years from now) | |
| US11052084 | INTRA-CELLULAR | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
Aug, 2039
(15 years from now) | |
| US11806348 | INTRA-CELLULAR | Methods of treatment using pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
Aug, 2039
(15 years from now) | |
| US10695345 | INTRA-CELLULAR | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
Aug, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 20, 2024 |
| New Indication(I-882) | Dec 17, 2024 |
Drugs and Companies using LUMATEPERONE TOSYLATE ingredient
NCE-1 date: 21 December, 2023
Market Authorisation Date: 22 April, 2022
Treatment: Treatment of schizophrenia mediated by the 5-ht2a receptor, serotonin transporter, and/or dopamine d1/d2 signaling pathways; Treatment of bipolar depression mediated by the 5-ht2a receptor, serotonin ...
Dosage: CAPSULE;ORAL
CAPLYTA family patents
13. Combogesic patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11534407 | AFT PHARMS LTD | Pharmaceutical compostion containing acetominophen and ibuprofen |
Feb, 2039
(14 years from now) | |
| US11197830 | AFT PHARMS LTD | Pharmaceutical composition containing acetaminophen and ibuprofen |
Feb, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 01, 2026 |
Drugs and Companies using ACETAMINOPHEN; IBUPROFEN ingredient
Market Authorisation Date: 01 March, 2023
Treatment: A method of treating mild to moderate acute pain in adults by administering 975-1000 mg of acetaminophen and 292.5-300 mg of ibuprofen in a single administration
Dosage: TABLET;ORAL
COMBOGESIC family patents
14. Cosela patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11529352 | G1 THERAP | Preservation of immune response during chemotherapy regimens |
Jul, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 12, 2026 |
Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient
NCE-1 date: 12 February, 2025
Market Authorisation Date: 12 February, 2021
Treatment: A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen that includes an immune checkpoint inhi...
Dosage: POWDER;INTRAVENOUS
COSELA family patents
15. Cuvrior patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10988436 | ORPHALAN | Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use |
May, 2039
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11072577 | ORPHALAN | Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use |
May, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 28, 2025 |
| Orphan Drug Exclusivity(ODE-401) | Apr 28, 2029 |
Drugs and Companies using TRIENTINE TETRAHYDROCHLORIDE ingredient
Market Authorisation Date: 28 April, 2022
Treatment: A method for the treatment of adult patients with stable wilson’s disease who are de-coppered and tolerant to penicillamine
Dosage: TABLET;ORAL
CUVRIOR family patents
16. Dexycu Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11097061 | EYEPOINT PHARMS | Systems, kits and methods for loading and delivering a small volume dose from a syringe |
Jun, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 09, 2021 |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 09 February, 2018
Treatment: A method of loading medication into a syringe and delivering the medication to a treatment site
Dosage: SUSPENSION;INTRAOCULAR
DEXYCU KIT family patents
17. Dhivy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11033521 | AVION PHARMS | Levodopa fractionated dose composition and use |
Mar, 2039
(14 years from now) | |
| US11819485 | AVION PHARMS | Levodopa fractionated dose composition and use |
Mar, 2039
(14 years from now) | |
| US11439613 | AVION PHARMS | Levodopa fractionated dose composition and use |
Mar, 2039
(14 years from now) | |
Drugs and Companies using CARBIDOPA; LEVODOPA ingredient
Market Authorisation Date: 12 November, 2021
Treatment: Method of treating parkinson's disease by orally administering a functionally multiscored, bilayered tablet having carbidopa—25 mg/levodopa—100 mg; Treatment of parkinson's disease, post-encephalitic ...
Dosage: TABLET;ORAL
DHIVY family patents
18. Elcys patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10918662 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US11510941 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US11510942 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US10905713 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US11684636 | EXELA PHARMA | Stable, highly pure l-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US11826383 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US10905714 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US11648262 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US10933089 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US10912795 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US10653719 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US11679125 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US10583155 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US10478453 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US11642370 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 April, 2019
Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition
Dosage: SOLUTION;INTRAVENOUS
ELCYS family patents
19. Elucirem patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10973934 | GUERBET | Gadolinium bearing PCTA-based contrast agents |
Aug, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 21, 2027 |
Drugs and Companies using GADOPICLENOL ingredient
NCE-1 date: 21 September, 2026
Market Authorisation Date: 21 September, 2022
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
ELUCIREM family patents
20. Epidiolex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11207292 | JAZZ PHARMS RES | Cannabidiol preparations and its uses |
Apr, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-216) | Sep 28, 2025 |
| Orphan Drug Exclusivity(ODE-332) | Jul 31, 2027 |
| Orphan Drug Exclusivity(ODE-326) | Jul 31, 2027 |
| M(M-270) | Oct 20, 2026 |
| New Chemical Entity Exclusivity(NCE) | Sep 28, 2023 |
| New Patient Population(NPP) | Jul 31, 2023 |
Drugs and Companies using CANNABIDIOL ingredient
NCE-1 date: 28 September, 2022
Market Authorisation Date: 28 September, 2018
Treatment: Use for the treatment of seizures associated with lennox-gastaut syndrome
Dosage: SOLUTION;ORAL
EPIDIOLEX family patents
21. Farxiga patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11826376 | ASTRAZENECA AB | Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same |
Jul, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-857) | Apr 30, 2024 |
| M(M-298) | May 08, 2026 |
| M(M-238) | Feb 22, 2022 |
| New Indication(I-834) | May 05, 2023 |
| M(M-212) | Oct 20, 2020 |
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| M(M-157) | Mar 11, 2018 |
| New Indication(I-841) | Oct 18, 2022 |
Drugs and Companies using DAPAGLIFLOZIN ingredient
NCE-1 date: 08 January, 2018
Market Authorisation Date: 08 January, 2014
Treatment: Reduce the risk of cardiovascular death and hospitalization for heart failure and urgent heart failure visits in adults with heart failure with preserved ejection fraction and without type ii diabetes
Dosage: TABLET;ORAL
FARXIGA family patents
22. Focinvez patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11065256 | STERISCIENCE | Administration and dosage of diaminophenothiazines |
Jan, 2039
(14 years from now) | |
| US11065265 | STERISCIENCE | Compositions of fosaprepitant and methods of preparation |
Jan, 2039
(14 years from now) | |
Drugs and Companies using FOSAPREPITANT DIMEGLUMINE ingredient
Market Authorisation Date: 22 August, 2023
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
FOCINVEZ family patents
23. Fotivda patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11504365 | AVEO PHARMS | Use of tivozanib to treat subjects with refractory cancer |
Nov, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 10, 2026 |
Drugs and Companies using TIVOZANIB HYDROCHLORIDE ingredient
NCE-1 date: 10 March, 2025
Market Authorisation Date: 10 March, 2021
Treatment: Treatment of adults with moderate hepatic impairment and relapsed or refractory advanced renal cell carcinoma following two or more prior systemic anti-cancer therapies with 1mg tivozanib hcl orally f...
Dosage: CAPSULE;ORAL
FOTIVDA family patents
24. Galafold patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11826360 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
Feb, 2039
(14 years from now) | |
| US11622962 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
Mar, 2039
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11357784 | AMICUS THERAP US | Use of migalastat for treating Fabry disease in pregnant patients |
Feb, 2039
(14 years from now) | |
| US11642334 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
Feb, 2039
(14 years from now) | |
| US11633388 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
Mar, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-205) | Aug 10, 2025 |
| New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: The treatment of fabry patients
Dosage: CAPSULE;ORAL
GALAFOLD family patents
25. Gavreto patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11273160 | GENENTECH INC | RET inhibitor for use in treating cancer having a RET alteration |
Apr, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 04, 2025 |
| Orphan Drug Exclusivity(ODE-341) | Dec 01, 2027 |
| Orphan Drug Exclusivity(ODE-340) | Dec 01, 2027 |
| Orphan Drug Exclusivity(ODE-318) | Sep 04, 2027 |
Drugs and Companies using PRALSETINIB ingredient
NCE-1 date: 04 September, 2024
Market Authorisation Date: 04 September, 2020
Treatment: Treatment of adult patients with metastatic rearranged during transfection (ret) fusion-positive non-small cell lung cancer (nsclc) as detected by an fda approved test
Dosage: CAPSULE;ORAL
GAVRETO family patents
26. Igalmi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11497711 | BIOXCEL | Film formulations containing dexmedetomidine and methods of producing them |
Jun, 2039
(15 years from now) | |
| US11478422 | BIOXCEL | Film formulations containing dexmedetomidine and methods of producing them |
Jun, 2039
(15 years from now) | |
| US11517524 | BIOXCEL | Film formulations containing dexmedetomidine and methods of producing them |
Jun, 2039
(15 years from now) | |
| US10792246 | BIOXCEL | Film formulations containing dexmedetomidine and methods of producing them |
Jun, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 05, 2025 |
Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 April, 2022
Treatment: Acute treatment of agitation associated with schizophrenia or bipolar i or ii disorder by buccal administration; Acute treatment of agitation associated with schizophrenia or bipolar i or ii disorder ...
Dosage: FILM;BUCCAL, SUBLINGUAL
IGALMI family patents
27. Ingrezza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11026931 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Aug, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-440) | Aug 18, 2030 |
| New Indication(I-925) | Aug 18, 2026 |
| New Chemical Entity Exclusivity(NCE) | Apr 11, 2022 |
Drugs and Companies using VALBENAZINE TOSYLATE ingredient
NCE-1 date: 11 April, 2021
Market Authorisation Date: 11 April, 2017
Treatment: Treatment of tardive dyskinesia
Dosage: CAPSULE;ORAL
INGREZZA family patents
28. Inrebic patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11400092 | IMPACT | Methods of treating myeloproliferative disorders |
Sep, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-259) | Aug 16, 2026 |
| New Chemical Entity Exclusivity(NCE) | Aug 16, 2024 |
Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient
NCE-1 date: 17 August, 2023
Market Authorisation Date: 16 August, 2019
Treatment: Treating adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis, monitoring thiamine levels and administering thiamine or a thiamine equivalent
Dosage: CAPSULE;ORAL
INREBIC family patents
29. Jatenzo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11564933 | TOLMAR | Methods of treating testosterone deficiency |
Apr, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 27, 2022 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 27 March, 2019
Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone
Dosage: CAPSULE;ORAL
JATENZO family patents
30. Katerzia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10799453 | AZURITY | Amlodipine formulations |
Apr, 2039
(14 years from now) | |
Drugs and Companies using AMLODIPINE BENZOATE ingredient
Market Authorisation Date: 08 July, 2019
Treatment: NA
Dosage: SUSPENSION;ORAL
KATERZIA family patents
31. Khapzory patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11541012 | ACROTECH BIOPHARMA | Compositions comprising disodium levofolinate |
Mar, 2039
(14 years from now) | |
Drugs and Companies using LEVOLEUCOVORIN ingredient
Market Authorisation Date: 19 October, 2018
Treatment: NA
Dosage: POWDER;INTRAVENOUS
KHAPZORY family patents
32. Konvomep patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10751333 | AZURITY | Compositions and kits for omeprazole suspension |
Jul, 2039
(15 years from now) | |
| US11103492 | AZURITY | Compositions and kits for omeprazole suspension |
Jul, 2039
(15 years from now) | |
| US11633478 | AZURITY | Compositions and kits for Omeprazole suspension |
Jul, 2039
(15 years from now) | |
Drugs and Companies using OMEPRAZOLE; SODIUM BICARBONATE ingredient
Market Authorisation Date: 30 August, 2022
Treatment: NA
Dosage: FOR SUSPENSION;ORAL
KONVOMEP family patents
33. Likmez patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11541035 | SAPTALIS PHARMS | Oral formulations of metronidazole and methods of treating an infection using same |
Oct, 2039
(15 years from now) | |
Drugs and Companies using METRONIDAZOLE ingredient
Market Authorisation Date: 22 September, 2023
Treatment: NA
Dosage: SUSPENSION;ORAL
LIKMEZ family patents
34. Lumason patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11723869 | BRACCO | Freeze-dried product and gas-filled microvesicles suspension |
May, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-728) | Mar 31, 2019 |
| New Chemical Entity Exclusivity(NCE) | Oct 10, 2019 |
| New Patient Population(NPP) | Nov 13, 2022 |
Drugs and Companies using SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES ingredient
NCE-1 date: 10 October, 2018
Market Authorisation Date: 15 October, 2014
Treatment: Use with ultrasound of the liver in adult and pediatric patients to characterize focal liver lesions
Dosage: FOR SUSPENSION;INTRAVENOUS
LUMASON family patents
35. Lytgobi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11833151 | TAIHO ONCOLOGY | Pharmaceutical composition including sodium alkyl sulfate |
Nov, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 30, 2027 |
| Orphan Drug Exclusivity(ODE-410) | Sep 30, 2029 |
Drugs and Companies using FUTIBATINIB ingredient
NCE-1 date: 30 September, 2026
Market Authorisation Date: 30 September, 2022
Treatment: NA
Dosage: TABLET;ORAL
LYTGOBI family patents
36. Lyvispah patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11654124 | AMNEAL | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives |
Jul, 2039
(15 years from now) | |
| US10792262 | AMNEAL | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives |
Jul, 2039
(15 years from now) | |
Drugs and Companies using BACLOFEN ingredient
Market Authorisation Date: 22 November, 2021
Treatment: Method for treating spasticity
Dosage: GRANULES;ORAL
LYVISPAH family patents
37. Mounjaro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11357820 | ELI LILLY AND CO | GIP/GLP1 agonist compositions |
Jun, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 13, 2027 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 July, 2023
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
MOUNJARO family patents
38. Norepinephrine Bitartrate In 0.9% Sodium Chloride patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10888534 | INFORLIFE | Storage stable ready-to-use norepinephrine aqueous solutions in flexible plastic bags |
Apr, 2039
(15 years from now) | |
Drugs and Companies using NOREPINEPHRINE BITARTRATE ingredient
Market Authorisation Date: 15 September, 2022
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE family patents
39. Nouress patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10583155 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US10478453 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US10912795 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US10933089 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US10905713 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US10905714 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US10918662 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US11510942 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US10653719 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US11510941 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Mar, 2039
(14 years from now) | |
| US11045438 | BAXTER HLTHCARE CORP | Cysteine composition and injection |
Mar, 2039
(14 years from now) | |
| US10493051 | BAXTER HLTHCARE CORP | Cysteine composition and injection |
Mar, 2039
(14 years from now) | |
| US10702490 | BAXTER HLTHCARE CORP | Cysteine composition and injection |
Mar, 2039
(14 years from now) | |
| US10543186 | BAXTER HLTHCARE CORP | Cysteine composition and injection |
Mar, 2039
(14 years from now) | |
Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient
Market Authorisation Date: 13 December, 2019
Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition; Method of intravenously administering a diluted cysteine hydrochloride solution to a neonate in need ther...
Dosage: SOLUTION;INTRAVENOUS
NOURESS family patents
40. Nurtec Odt patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11083724 | PFIZER | Rimegepant for CGRP related disorders |
Mar, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 27, 2025 |
| New Indication(I-865) | May 27, 2024 |
Drugs and Companies using RIMEGEPANT SULFATE ingredient
NCE-1 date: 28 February, 2024
Market Authorisation Date: 27 February, 2020
Treatment: Preventive treatment of episodic migraine in adults
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
NURTEC ODT family patents
41. Ogsiveo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10710966 | SPRINGWORKS | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
Aug, 2039
(15 years from now) | |
| US11845732 | SPRINGWORKS | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
Aug, 2039
(15 years from now) | |
| US10590087 | SPRINGWORKS | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
Aug, 2039
(15 years from now) | |
| US10941118 | SPRINGWORKS | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
Aug, 2039
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11820748 | SPRINGWORKS | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
Aug, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-452) | Nov 27, 2030 |
| New Chemical Entity Exclusivity(NCE) | Nov 27, 2028 |
Drugs and Companies using NIROGACESTAT HYDROBROMIDE ingredient
NCE-1 date: 28 November, 2027
Market Authorisation Date: 27 November, 2023
Treatment: Treatment of adult patients with progressing desmoid tumors
Dosage: TABLET;ORAL
OGSIVEO family patents
42. Omlonti patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11666563 | VISIOX PHARMA | Pharmaceutical preparation containing pyridyl aminoacetic acid compound |
Jul, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 22, 2027 |
Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient
NCE-1 date: 22 September, 2026
Market Authorisation Date: 22 September, 2022
Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients
Dosage: SOLUTION;OPHTHALMIC
OMLONTI family patents
43. Oriahnn (copackaged) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11542239 | ABBVIE | Elagolix sodium compositions and processes |
Jul, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2023 |
| New Product(NP) | May 29, 2023 |
NCE-1 date: 23 July, 2022
Market Authorisation Date: 29 May, 2020
Treatment: NA
Dosage: CAPSULE;ORAL
ORIAHNN (COPACKAGED) family patents
44. Orilissa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11542239 | ABBVIE | Elagolix sodium compositions and processes |
Jul, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2023 |
Drugs and Companies using ELAGOLIX SODIUM ingredient
NCE-1 date: 23 July, 2022
Market Authorisation Date: 23 July, 2018
Treatment: NA
Dosage: TABLET;ORAL
ORILISSA family patents
45. Orladeyo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10662160 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11117867 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(15 years from now) | |
| US11618733 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-333) | Dec 03, 2027 |
| New Chemical Entity Exclusivity(NCE) | Dec 03, 2025 |
Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient
NCE-1 date: 03 December, 2024
Market Authorisation Date: 03 December, 2020
Treatment: Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older
Dosage: CAPSULE;ORAL
ORLADEYO family patents
46. Ozobax patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10610502 | METACEL PHARMS LLC | Oral baclofen solutions |
Aug, 2039
(15 years from now) | |
Drugs and Companies using BACLOFEN ingredient
Market Authorisation Date: 18 September, 2019
Treatment: Treatment of spasticity
Dosage: SOLUTION;ORAL
OZOBAX family patents
47. Pedmark patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11510984 | FENNEC PHARMS INC | Anhydrous sodium thiosulfate and formulations thereof |
Jul, 2039
(15 years from now) | |
| US11291728 | FENNEC PHARMS INC | Anhydrous sodium thiosulfate and formulations thereof |
Jul, 2039
(15 years from now) | |
| US11617793 | FENNEC PHARMS INC | Anhydrous sodium thiosulfate and formulations thereof |
Jul, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 20, 2025 |
| Orphan Drug Exclusivity(ODE-384) | Sep 20, 2029 |
Drugs and Companies using SODIUM THIOSULFATE ingredient
Market Authorisation Date: 20 September, 2022
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
PEDMARK family patents
48. Pemazyre patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11466004 | INCYTE CORP | Solid forms of an FGFR inhibitor and processes for preparing the same |
May, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2025 |
| Orphan Drug Exclusivity(ODE-292) | Apr 17, 2027 |
| Orphan Drug Exclusivity(ODE-404) | Aug 26, 2029 |
| New Indication(I-899) | Aug 26, 2025 |
Drugs and Companies using PEMIGATINIB ingredient
NCE-1 date: 17 April, 2024
Market Authorisation Date: 17 April, 2020
Treatment: Treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering pemigatinib in a daily dose of about 5 mg to...
Dosage: TABLET;ORAL
PEMAZYRE family patents
49. Potassium Phosphates patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10632150 | CMP DEV LLC | Potassium phosphates composition for injection |
Apr, 2039
(14 years from now) | |
Drugs and Companies using POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC ingredient
Market Authorisation Date: 19 September, 2019
Treatment: Potassium phosphates injection is indicated as a source of phosphorus in intravenous fluids to correct hypophosphatemia in adults and pediatric patients 12 years of age and older
Dosage: SOLUTION;INTRAVENOUS
POTASSIUM PHOSPHATES family patents
50. Proair Digihaler patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11344685 | TEVA BRANDED PHARM | Drug delivery device with electronics |
Sep, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 12, 2018 |
| New Patient Population(NPP) | Apr 28, 2019 |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 21 December, 2018
Treatment: NA
Dosage: POWDER, METERED;INHALATION
PROAIR DIGIHALER family patents
51. Qvar Redihaler patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10792447 | NORTON WATERFORD | Breath actuated inhaler |
Jan, 2039
(14 years from now) | |
| US11559637 | NORTON WATERFORD | Inhalers and related methods |
Jul, 2039
(15 years from now) | |
Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient
Market Authorisation Date: 03 August, 2017
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
QVAR REDIHALER family patents
52. Radicava Ors patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11241416 | MITSUBISHI TANABE | Edaravone suspension for oral administration |
Nov, 2039
(15 years from now) | |
| US11826352 | MITSUBISHI TANABE | Edaravone suspension for oral administration |
Nov, 2039
(15 years from now) | |
| US11478450 | MITSUBISHI TANABE | Edaravone suspension for oral administration |
Nov, 2039
(15 years from now) | |
| US10987341 | MITSUBISHI TANABE | Edaravone suspension for oral administration |
Nov, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-144) | May 12, 2029 |
| New Product(NP) | May 12, 2025 |
Drugs and Companies using EDARAVONE ingredient
Market Authorisation Date: 12 May, 2022
Treatment: Treatment of amyotrophic lateral sclerosis
Dosage: SUSPENSION;ORAL
RADICAVA ORS family patents
53. Rezlidhia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10532047 | RIGEL PHARMS INC | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10959994 | RIGEL PHARMS INC | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(15 years from now) | |
| US11013733 | RIGEL PHARMS INC | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
May, 2039
(15 years from now) | |
| US11376246 | RIGEL PHARMS INC | Inhibiting mutant IDH-1 |
May, 2039
(15 years from now) | |
| US11013734 | RIGEL PHARMS INC | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
May, 2039
(15 years from now) | |
| US11497743 | RIGEL PHARMS INC | Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation |
May, 2039
(15 years from now) | |
| US11738018 | RIGEL PHARMS INC | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
Jul, 2039
(15 years from now) | |
| US11723905 | RIGEL PHARMS INC | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
Nov, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 01, 2027 |
| Orphan Drug Exclusivity(ODE-413) | Dec 01, 2029 |
Drugs and Companies using OLUTASIDENIB ingredient
NCE-1 date: 01 December, 2026
Market Authorisation Date: 01 December, 2022
Treatment: A method of treating a cancer characterized by an idh1 mutation where the cancer is acute myeloid leukemia (aml); A method of treating acute myeloid leukemia (aml) in patients with an isocitrate dehyd...
Dosage: CAPSULE;ORAL
REZLIDHIA family patents
54. Sotalol Hydrochloride patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10799138 | ALTATHERA PHARMS LLC | Method of administering sotalol IV/switch |
Apr, 2039
(14 years from now) | |
| US11583216 | ALTATHERA PHARMS LLC | Method of administering sotalol IV/switch |
Aug, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jul 02, 2016 |
Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient
Market Authorisation Date: 02 July, 2009
Treatment: Use for loading dose in patients with symptomatic afib/afl who are currently in sinus rhythm or for the treatment of life-threatening ventricular tachycardia; Intravenous sotalol dosing regimen for us...
Dosage: SOLUTION;INTRAVENOUS
SOTALOL HYDROCHLORIDE family patents
55. Spy Agent Green Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11712320 | NOVADAQ TECH | Methods and systems to automate surgical interventions |
Jul, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-911) | Jun 05, 2026 |
| New Product(NP) | Nov 21, 2021 |
Drugs and Companies using INDOCYANINE GREEN ingredient
Market Authorisation Date: 21 November, 2018
Treatment: NA
Dosage: POWDER;INTRAVENOUS, INTERSTITIAL
SPY AGENT GREEN KIT family patents
56. Sunosi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11560354 | AXSOME MALTA | Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof |
Mar, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2024 |
| Orphan Drug Exclusivity(ODE-254) | Jun 17, 2026 |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
NCE-1 date: 18 June, 2023
Market Authorisation Date: 17 June, 2019
Treatment: Treatment of excessive daytime sleepiness by administering a composition comprising solriamfetol hydrochloride and 2-chloropropane, wherein the composition comprises less than about 5 ppm 2‑chloroprop...
Dosage: TABLET;ORAL
SUNOSI family patents
57. Testosterone Cypionate patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11642355 | SLAYBACK PHARMA LLC | Pharmaceutical compositions of testosterone |
Mar, 2039
(14 years from now) | |
| US11311554 | SLAYBACK PHARMA LLC | Pharmaceutical compositions of testosterone |
Mar, 2039
(14 years from now) | |
Drugs and Companies using TESTOSTERONE CYPIONATE ingredient
Market Authorisation Date: 02 June, 2022
Treatment: NA
Dosage: SOLUTION;INTRAMUSCULAR
TESTOSTERONE CYPIONATE family patents
58. Tibsovo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10980788 | SERVIER | Therapy for treating malignancies |
Jun, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-203) | Jul 20, 2025 |
| Orphan Drug Exclusivity(ODE-242) | May 02, 2026 |
| New Indication(I-875) | Aug 25, 2024 |
| New Indication(I-924) | Oct 24, 2026 |
| Orphan Drug Exclusivity(ODE-368) | Aug 25, 2028 |
| Orphan Drug Exclusivity(ODE-447) | Oct 24, 2030 |
| New Indication(I-893) | May 25, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2023 |
| New Indication(I-816) | May 02, 2022 |
Drugs and Companies using IVOSIDENIB ingredient
NCE-1 date: 20 July, 2022
Market Authorisation Date: 20 July, 2018
Treatment: Treating relapsed/refractory acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of idh1 by administering a once daily 500 mg oral dose to a subject that has not ingested...
Dosage: TABLET;ORAL
TIBSOVO family patents
59. Tirosint-sol patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11241382 | IBSA | Administration regimen of compositions of T4 thyroid hormone with high oral absorption |
Sep, 2039
(15 years from now) | |
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 15 December, 2016
Treatment: Treatment of pituitary thyrotropin suppression by oral administration of l-thyroxine to a patient on an empty stomach 15 minutes before breakfast
Dosage: SOLUTION;ORAL
TIROSINT-SOL family patents
60. Trudhesa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11185497 | IMPEL PHARMS | Intranasal delivery of dihydroergotamine by precision olfactory device |
Jan, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 02, 2024 |
Drugs and Companies using DIHYDROERGOTAMINE MESYLATE ingredient
Market Authorisation Date: 02 September, 2021
Treatment: Nasal administration of dihydroergotamine mesylate by metered spray for the acute treatment of migraine with or without aura
Dosage: SPRAY, METERED;NASAL
TRUDHESA family patents
61. Upneeq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11103482 | RVL PHARMS | Oxymetazoline compositions |
Dec, 2039
(15 years from now) | |
| US10814001 | RVL PHARMS | Oxymetazoline compositions |
Dec, 2039
(15 years from now) | |
| US11541036 | RVL PHARMS | Oxymetazoline compositions |
Dec, 2039
(15 years from now) | |
| US11324722 | RVL PHARMS | Compositions and methods for treating ocular disorders |
Dec, 2039
(15 years from now) | |
| US11311515 | RVL PHARMS | Oxymetazoline compositions |
Dec, 2039
(15 years from now) | |
| US10940138 | RVL PHARMS | Compositions and methods for treating ocular disorders |
Dec, 2039
(15 years from now) | |
| US11701343 | RVL PHARMS | Compositions and methods for treating ocular disorders |
Dec, 2039
(15 years from now) | |
| US10898573 | RVL PHARMS | Oxymetazoline compositions |
Dec, 2039
(15 years from now) | |
| US10799481 | RVL PHARMS | Compositions and methods for treating ocular disorders |
Dec, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 08, 2023 |
Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 08 July, 2020
Treatment: Method of treating blepharoptosis
Dosage: SOLUTION/DROPS;OPHTHALMIC
UPNEEQ family patents
62. Vabomere patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11376237 | REMPEX | Methods of treating bacterial infections |
Apr, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 29, 2022 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 29, 2027 |
Drugs and Companies using MEROPENEM; VABORBACTAM ingredient
NCE-1 date: 29 August, 2026
Market Authorisation Date: 29 August, 2017
Treatment: Treatment of complicated urinary tract infections (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli,klebsiella pneumonia,enterobacter cloacae species...
Dosage: POWDER;INTRAVENOUS
VABOMERE family patents
63. Vevye patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11413323 | HARROW EYE | Ophthalmic composition for treatment of dry eye disease |
Oct, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 30, 2026 |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 30 May, 2023
Treatment: Treatment of dry eye disease (ded)
Dosage: SOLUTION;OPHTHALMIC
VEVYE family patents
64. Vtama patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11590088 | DERMAVANT SCI | Use of Tapinarof for the treatment of chronic plaque psoriasis |
Nov, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 23, 2027 |
Drugs and Companies using TAPINAROF ingredient
NCE-1 date: 23 May, 2026
Market Authorisation Date: 23 May, 2022
Treatment: Topical treatment of plaque psoriasis in adults
Dosage: CREAM;TOPICAL
VTAMA family patents
65. Vuity patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10610518 | ABBVIE | Presbyopia treatments |
Apr, 2039
(15 years from now) | |
| US11285134 | ABBVIE | Presbyopia treatments |
Apr, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-187) | Mar 28, 2026 |
| New Product(NP) | Oct 28, 2024 |
Drugs and Companies using PILOCARPINE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 October, 2021
Treatment: Use of vuity for the treatment of presbyopia in adults
Dosage: SOLUTION;OPHTHALMIC
VUITY family patents
66. Wynzora patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11638711 | MC2 | NULL |
Mar, 2039
(14 years from now) | |
| US11696919 | MC2 | Topical composition |
Mar, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jul 20, 2023 |
Drugs and Companies using BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE ingredient
Market Authorisation Date: 20 July, 2020
Treatment: NA
Dosage: CREAM;TOPICAL
WYNZORA family patents
67. Xarelto patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10828310 | JANSSEN PHARMS | Reducing the risk of cardiovascular events |
Jan, 2039
(14 years from now) | |
|
US10828310 (Pediatric) | JANSSEN PHARMS | Reducing the risk of cardiovascular events |
Jul, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-867) | Aug 23, 2024 |
| Pediatric Exclusivity(PED) | Feb 23, 2025 |
| New Indication(I-824) | Oct 11, 2021 |
| New Dosing Schedule(D-168) | Oct 27, 2020 |
| New Indication(I-810) | Oct 11, 2022 |
| M(M-284) | Mar 10, 2023 |
| New Indication(I-660) | Nov 02, 2015 |
| New Indication(I-661) | Nov 02, 2015 |
| New Indication(I-662) | Nov 02, 2015 |
| New Chemical Entity Exclusivity(NCE) | Jul 01, 2016 |
| New Indication(I-643) | Nov 04, 2014 |
Drugs and Companies using RIVAROXABAN ingredient
NCE-1 date: 24 February, 2024
Market Authorisation Date: 11 October, 2018
Treatment: Reduction of risk of myocardial infarction and ischemic stroke in patients with pad by administering clinically proven effective amounts that are 2.5 mg rivaroxaban twice daily and 75-100 mg aspirin d...
Dosage: TABLET;ORAL
XARELTO family patents
68. Xcopri patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11654133 | SK LIFE | Use of [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate in combination therapy |
Jun, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 10, 2025 |
Drugs and Companies using CENOBAMATE ingredient
NCE-1 date: 10 March, 2024
Market Authorisation Date: 10 March, 2020
Treatment: Co-administration of cenobamate with phenobarbital and/or phenytoin for the treatment of partial onset seizures
Dosage: TABLET;ORAL
XCOPRI family patents
69. Yupelri patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11484531 | MYLAN IRELAND LTD | Methods for treating chronic obstructive pulmonary disease |
Oct, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 09, 2023 |
Drugs and Companies using REVEFENACIN ingredient
NCE-1 date: 09 November, 2022
Market Authorisation Date: 09 November, 2018
Treatment: For the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: SOLUTION;INHALATION
YUPELRI family patents
70. Zejula patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11730725 | GLAXOSMITHKLINE | Niraparib formulations |
Jan, 2039
(14 years from now) | |
Drugs and Companies using NIRAPARIB TOSYLATE ingredient
Market Authorisation Date: 26 April, 2023
Treatment: NA
Dosage: TABLET;ORAL
ZEJULA family patents
71. Zepbound patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11357820 | ELI LILLY AND CO | GIP/GLP1 agonist compositions |
Jun, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 08, 2026 |
| New Chemical Entity Exclusivity(NCE) | May 13, 2027 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 March, 2024
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
ZEPBOUND family patents
72. Zimhi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11027072 | ADAMIS PHARMS CORP | Emergency devices |
May, 2039
(15 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 October, 2021
Treatment: NA
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
ZIMHI family patents
List of large molecules
1. List of Eylea large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US10973879 | REGENERON PHARMACEUTICALS, INC. | Use of a VEGF antagonist to treat angiogenic eye disorders |
May, 2039
(15 years from now) | |
| US11160918 | REGENERON PHARMACEUTICALS, INC. | Medical device packaging and related methods |
Jul, 2039
(15 years from now) |
Ingredients: AFLIBERCEPT